文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

基孔肯雅疫苗的研发、挑战及实现公共卫生影响的路径

Chikungunya vaccine development, challenges, and pathway toward public health impact.
PubMed 文献 · Vaccine · 2024-10-29

基孔肯雅是一种被忽视的热带病,自2004年以来在亚洲、非洲、美洲、欧洲和大洋洲超过114个国家出现疫情,目前无特异性抗病毒治疗。本文描述基孔肯雅疫苗研发管线,评估疫苗获批、可及性和接种面临的挑战,并倡导成立全球基孔肯雅疫苗联盟以克服相关障碍。

要点

  • Ixchiq(VLA1533/Ixchiq - Valneva)是首个获批的基孔肯雅疫苗,2023年11月获美国食品药品监督管理局批准。
  • 五种候选疫苗正在研发中:BBV87、MV-CHIK、ChAdOx1 Chik、PXVX0317/VRC-CHKVLP059-00-VP和mRNA-1388。
  • 本文倡导成立包括监管机构、政策制定者、申办方和制造商在内的全球基孔肯雅疫苗联盟。

核心结论

  • 基孔肯雅疫苗的引入决策需要疾病负担证据以及疫苗接种的公共卫生和经济影响证据。
  • 全球和区域利益相关方需就可持续的规模化生产融资机制达成一致,以促进公平可及和公平分配。
  • 本文倡导成立全球基孔肯雅疫苗联盟,以协助克服疫苗获批、政策、融资、需求生成和可及性方面的全球和地方挑战。

研究设计与样本

  • 本文为综述,描述基孔肯雅疫苗研发管线并评估疫苗获批、可及性和接种的挑战。

主要发现

  • 自2004年以来,基孔肯雅在亚洲、非洲、美洲、欧洲和大洋洲超过114个国家出现疫情。
  • 基孔肯雅病毒感染无特异性抗病毒治疗选择。
  • Ixchiq(VLA1533/Ixchiq - Valneva)于2023年11月获美国食品药品监督管理局批准,2024年5月获欧洲药品管理局批准,2024年6月获加拿大卫生部批准,成为首个获批的基孔肯雅疫苗。
  • 五种基孔肯雅候选疫苗正在研发中:BBV87(BBIL/IVI)、MV-CHIK(Themis Bioscience)、ChAdOx1 Chik(牛津大学)、PXVX0317/VRC-CHKVLP059-00-VP(Bavarian Nordic)和mRNA-1388(Moderna)。

关键数值与推荐

  • 首个获批的基孔肯雅疫苗为Ixchiq(VLA1533/Ixchiq - Valneva),获批机构及时间:美国食品药品监督管理局2023年11月、欧洲药品管理局2024年5月、加拿大卫生部2024年6月。
  • 五种候选疫苗处于研发阶段:BBV87、MV-CHIK、ChAdOx1 Chik、PXVX0317/VRC-CHKVLP059-00-VP、mRNA-1388。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chikungunya is a neglected tropical disease of growing public health concern with outbreaks in more than 114 countries in Asia, Africa, Americas, Europe, and Oceania since 2004. There are no specific antiviral treatment options for chikungunya virus infection. This article describes the chikungunya vaccine pipeline and assesses the challenges in the path to licensure, access, and uptake of chikungunya vaccines in populations at risk. Ixchiq (VLA1533/Ixchiq - Valneva) was the first licensed chikungunya vaccine by the US Food and Drug Administration in November 2023, European Medicines Agency in May 2024, and Health Canada in June 2024. Five chikungunya vaccine candidates (BBV87 - BBIL/IVI, MV-CHIK - Themis Bioscience, ChAdOx1 Chik - University of Oxford, PXVX0317 / VRC-CHKVLP059-00-VP - Bavarian Nordic, and mRNA-1388 - Moderna) are in development. Evidence on chikungunya disease burden alongside the public health and economic impact of vaccination are critical for decision-making on chikungunya vaccine introduction in endemic and epidemic settings. Further, global and regional stakeholders need to agree on a sustainable financing mechanism for manufacturing at scale to facilitate fair access and equitable vaccine distribution to at-risk populations in different geographic settings. This could partly be facilitated through obtaining consensus on scientific and regulatory principles for initial vaccine introduction and generating evidence on chikungunya burden and disease awareness among populations at risk. Specifically, this article advocates for the formation of a global chikungunya vaccine consortium that includes regulators, policymakers, sponsors, and manufacturers to assist in overcoming the global and local challenges for chikungunya vaccine licensure, policy, financing, demand generation, and access to at-risk populations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Maure C, Khazhidinov K, Kang H, et al. Chikungunya vaccine development, challenges, and pathway toward public health impact. Vaccine. 2024. PMID: 39467413. doi:10.1016/j.vaccine.2024.126483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。